Indonesia Cancer Immunotherapy Market Analysis

Indonesia Cancer Immunotherapy Market Analysis


$ 3999

Indonesia's cancer immunotherapy market is expected to grow from $675 Mn in 2022 to $1,169 Mn in 2030 with a CAGR of 7.1% for the forecasted year 2022-30. The rising prevalence of cancer and supportive government policies to promote immunotherapy options in Indonesia is responsible for the expansion of the market. The Indonesia cancer immunotherapy market is segmented by type, application, and end user. Asa Rén, Cordlife, and Bristol-Myers Squibb are the major players in the Indonesia cancer immunotherapy market.

ID: IN10IDPH032 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Dr. Parul Choudhary

Buy Now

Indonesia Cancer Immunotherapy Market Executive Analysis

Indonesia's cancer immunotherapy market is expected to grow from $675 Mn in 2022 to $1,169 Mn in 2030 with a CAGR of 7.1% for the forecasted year 2022-30. 5.6 % of all state spending, or $11 Bn, has been set aside by the Indonesian government for health. The National Health Insurance (JKN) program will be maintained, the health system will be reformed, stunting will be reduced more quickly, and the funds will be used to address the epidemic.

According to the World Health Organization (WHO), with almost 397,000 cancer diagnoses in 2020, cancer will be the fourth largest cause of death in Indonesia. More than 70% of those with cancer had already received an advanced diagnosis when they entered a medical facility for the first time. Palliative care in these cases of advanced disease must concentrate on raising the patient's quality of life. Yet only 1% of Indonesians with advanced cancer have access to palliative treatment.

In Indonesia, the field of cancer immunotherapy is expanding quickly and is playing a bigger role in the country's approach to cancer treatment. A form of cancer treatment known as immunotherapy uses the immune system's power to combat cancer cells. Immunotherapy is frequently employed in Indonesia to treat advanced cancers such as melanoma, lung, bladder, and kidney tumours. Indonesia offers a range of immunotherapy therapies, including cancer vaccines, CAR-T cell therapy, and checkpoint inhibitors. The Indonesian government has put regulations into place recently to increase access to cancer treatments, including immunotherapy. The Indonesian government has made investments in medical staff, technology, and facilities for cancer treatment. Patients have easier access to immunotherapy therapies because some of them are funded by Indonesia's national health insurance program.

Indonesia Cancer Immunotherapy Market Analysis

Market Dynamics

Market Growth Drivers

The prevalence of cancer is rising in Indonesia, which has led to a rise in demand for efficient cancer therapies like immunotherapy. The Indonesian government has put laws in place to promote access to healthcare, particularly cancer immunotherapy, and has acknowledged the significance of cancer treatment. The Indonesia cancer immunotherapy market is expanding as a result of new cancer immunotherapy technologies and medicines that provide more efficient and minimally invasive cancer treatments. The need for cancer immunotherapy therapies is anticipated to rise as healthcare spending rises as Indonesia's economy expands.

Market Restraints

Cancer immunotherapy therapies can be costly, which may restrict the number of patients in Indonesia who can receive them, especially those who cannot afford to pay for their own care. It's possible that many patients and healthcare professionals in Indonesia are unaware of the advantages of cancer immunotherapy or lack the information necessary to employ these treatments successfully.  The regulatory climate in Indonesia might make it difficult to develop and approve new cancer immunotherapy treatments, which might impede the Indonesia cancer immunotherapy market expansion.

Competitive Landscape

Key Players

  • Nalagenetics (IDN)
  • Syngenta (IDN)
  • Formulatrix (IDN)
  • Asa Rén (IDN)
  • Cordlife (IDN)
  • Bristol-Myers Squibb
  • ELI Lilly
  • F Hoffman-La Roche
  • Janssen
  • Merck
  • Novartis
  • Pfizer

Healthcare Policies and Regulatory Landscape

The Indonesian government has enacted several programs to enhance citizen access to healthcare services, including cancer treatment. A variety of cancer therapies, including immunotherapy, are covered by the Jaminan Kesehatan Nasional (JKN) national health insurance program in Indonesia. Chemotherapy, radiation therapy, and surgery are just a few of the cancer therapies that cancer patients can get reimbursed for under JKN. For the treatment of some cancers, JKN additionally provides coverage for immunotherapy medications including checkpoint inhibitors. The government has also put laws into place to promote early identification and treatment of cancer as well as raise public awareness of the disease. The National Cancer Control Strategy (NCCS), which seeks to enhance cancer prevention, diagnosis, treatment, and palliative care in Indonesia, is an example of such a policy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Immunotherapy Segmentation

By Type (Revenue, USD Billion):

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • PD-1/PD-L1
  • CTLA-4

By Application (Revenue, USD Billion):

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

By End User (Revenue, USD Billion):

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Cancer Research Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Asa Rén, Cordlife, and Bristol-Myers Squibb are the major players in the Indonesia cancer immunotherapy market.

The Indonesia cancer immunotherapy market is expected to grow from $675 Mn in 2022 to $1,169 Mn in 2030 with a CAGR of 7.1% for the forecasted year 2022-2030.

The Indonesia cancer immunotherapy market is segmented by type, application, and end user.


Last updated on: 06 October 2023
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up